Lundbeck, Teva sales and marketing update

The companies launched TEVA's Azilect in the U.K. to treat Parkinson's disease (PD). The monoamine oxidase B (MAO-B) inhibitor is approved as monotherapy in patients with early PD and as an adjunct ...